Find Clinical Trials | Cedars-Sinai

25 results found

Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Lung, Melanoma

Pfizer Inc, C5901001, Ph 1, Open-Label, Multi-Center, Melanoma, Solid Tumor, PF-08046031

Primary -To characterize the safety and tolerability profile of PF-08046031 in participants with advanced melanomas and select solid tumors (Parts 1, 2, 3) -To identify the MTD or MAD of PF-08046031 (Part 1) -To identify a recommended dose for ...

Colon, Lung, Melanoma, Other Female Genital, Thyroid, Unknown Sites

Pierre Fabre Médicament, KN-8701/KIN2787CI101, Ph1/1b, open label, Solid Tumors, KIN-2787

2. Study Objectives 2.1. Part A Dose Escalation 2.1.1. Part A1: KIN-2787 Monotherapy Dose Escalation -The primary objectives of Part A1 are to determine the safety and tolerability of PO administration of KIN-2787 including DLTs in ...

Melanoma

mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma

The purpose of this study is to examine whether the investigational combination of the drugs pembrolizumab and mRNA-4157 work better than pembrolizumab alone to prevent recurrence in high-risk melanoma. The study will also evaluate the ...

Melanoma

Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma

This study focuses on individuals who have advanced melanoma cancer that is currently being treated with one immunotherapy drug (anti-PD-1 drugs nivolumab or pembrolizumab) or a combination of nivolumab and ipilimumab. Researchers aim to determine ...

Melanoma

Melanoma Margins Trial: 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma

This study focuses on individuals who have been diagnosed with a form of skin cancer called melanoma, which develops from melanocytes (pigment cells). During surgery for melanoma, the skin cancer and a small margin of ...